Glenmark Pharma get USFDA nod for human trial of cancer-treating drug

By inhibiting HPK1, GRC 54276 is designed to potentially enhance the patient's own immune system to fight cancers, it added

Press Trust of India New Delhi
Glenmark Pharmaceuticals

Glenmark Pharmaceuticals on Thursday said its arm has received acceptance from the US health regulator to proceed with a phase 1/2, first-in-human trial for its investigational new drug aimed for treatment of patients with advanced cancers.

In a regulatory filing, the company said Glenmark Specialty SA received the acceptance from the US Food and Drug Administration (USFDA) for the investigational new drug (IND) application 'GRC 54276' for the treatment of patients with advanced solid tumours and lymphomas.

Developed by Glenmark, GRC 54276 is an orally available, small molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor. HPK1-regulated functions are involved in nearly every step of the cancer-immunity cycle, making it an attractive target for immuno-oncology, the company said.

By inhibiting HPK1, GRC 54276 is designed to potentially enhance the patient's own immune system to fight cancers, it added.

"Now that the (US)FDA has accepted our IND application, we look forward to initiating the ongoing Phase 1/2 study at the US sites. This is an important milestone for Glenmark as we continue to advance our oncology pipeline," Glenmark Pharmaceuticals Ltd Chief scientific officer and President, innovative Medicine Group, Nikhil Amin said.

A Phase 1/2 multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of GRC 54276 is currently underway in India, the company said.

Also Read

Researchers take closer look at DNA repair scheme for cancer therapy

Drug firm Glenmark gets USFDA nod for generic diabetes drug to market in US

Vaccine against cervical cancer to be included by mid-2023: NTAGI chief

Glenmark Pharma receives USFDA approval for generic antibiotic drug

USFDA issues warning letter to Glenmark Pharma for lapses at Goa plant

myTVS to set up centres in 3 Asia Pacific nations for overseas foray

Malaysia's Petronas offers $460 mn for stake in NTPC's green arm: Report

OYO rolls out accelerator programme for small first-generation hoteliers

OYO launches accelerator programme for first-generation hoteliers

Amid global tech churning, Salesforce announces expansion plans in India

So far 16 patients with various types of advanced cancers have been enrolled in this ongoing study in India, and the company plans to expand the study at ex-India research sites in the subsequent months, it added.

First Published: Mar 16 2023 | 6:14 PM IST